Results 21 to 30 of about 362,059 (246)

Enhancement of teprenone isomer separation by subcritical fluid chromatography using porous graphitic carbon column

open access: yesJournal of Analytical Science and Technology, 2021
Teprenone is a therapeutic anti-ulcer agent developed in Japan. As described in the Japanese Pharmacopoeia (JP) 17th Edition, gas chromatography/hydrogen flame ionization detection (GC/FID) and high-performance liquid chromatography/ultraviolet detection
Chang Hwa Jin   +4 more
doaj   +1 more source

α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice

open access: yesPharmaceutics, 2021
Fabry disease (FD) is a monogenic X-linked lysosomal storage disorder caused by a deficiency in the lysosomal enzyme α-Galactosidase A (α-Gal A). It is a good candidate to be treated with gene therapy, in which moderately low levels of enzyme activity ...
Julen Rodríguez-Castejón   +6 more
doaj   +1 more source

The PADMET platform - pharmacokinetic characterization of carbohydrate mimetics [PDF]

open access: yes, 2012
More than two decades ago it was realized that drug discovery and development strategies focusing exclusively on affinity enhancement and potency are unsuccessful.
Wittwer, Matthias Beat
core   +1 more source

Role of pharmacists in the management of patients with obesity [PDF]

open access: yesArhiv za farmaciju
Obesity, a chronic disease, is increasingly prevalent worldwide, posing a significant public health challenge. It is often accompanied by comorbidities such as hypertension, cardiovascular disease, dyslipidemia, and diabetes, among others.
Jovanović Marija   +2 more
doaj   +1 more source

Ocular Pharmacokinetic/Pharmacodynamic Modeling for Timolol in Rabbits Using a Telemetry System [PDF]

open access: yes, 2008
We have established an ocular pharmacokinetic/pharmacodynamic (PK/PD) model for a β-adrenergic antagonist, timolol, after instillation into rabbits. Timolol concentrations were determined by HPLC in the tear fluid, aqueous humor, cornea, and iris-ciliary
Sasaki, Hitoshi   +8 more
core   +1 more source

Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease

open access: yesNanomaterials, 2022
Gene supplementation therapy with plasmid DNA (pDNA) represents one of the most promising strategies for the treatment of monogenic diseases such as Fabry disease (FD).
Julen Rodríguez-Castejón   +5 more
doaj   +1 more source

AtriplaR/anti-TB Combination in TB/HIV Patients. Drug in Focus. [PDF]

open access: yes, 2011
Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS. Concurrent use of rifampicin and several antiretroviral
Semvua Hadija H   +5 more
core   +1 more source

Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib

open access: yesPharmaceutics
Background: Asciminib (Scemblix®) is approved for the first-line treatment of adult patients with chronic myeloid leukemia in the chronic phase at 40 mg twice daily (BID) and 80 mg once daily (QD) or 200 mg BID for patients harboring the T315I mutation ...
Ioannis Loisios-Konstantinidis   +3 more
doaj   +1 more source

Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

open access: yesJournal of Intensive Care, 2022
Background Levetiracetam pharmacokinetics is extensively altered in critically ill patients with augmented renal clearance (ARC). Consequently, the dosage regimens commonly used in clinical practice may not be sufficient to achieve target plasma ...
Idoia Bilbao-Meseguer   +7 more
doaj   +1 more source

Pharmacokinetic and Pharmacodynamic Characteristics of a new Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated Plasmodium Falciparum Malaria. [PDF]

open access: yes, 2011
The pharmacokinetic and pharmacodynamic properties of a new pediatric formulation of artemether-lumefantrine, dispersible tablet, were determined within the context of a multicenter, randomized, parallel-group study.
Lyimo, John   +16 more
core   +1 more source

Home - About - Disclaimer - Privacy